Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 8/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394882 | 0.84 | LPL (0.43) | IDO1TDO2IRAK4LPLLIPG | |
| SCHEMBL23638441 | 0.83 | FFAR1 (0.39) | IDO1TDO2IRAK4LPLLIPG | |
| SCHEMBL17113584 | 0.81 | LPL (0.41) | IDO1TDO2IRAK4LPLLIPG | |
| SCHEMBL23546464 | 0.81 | LPL (0.35) | IDO1TDO2IRAK4LPLLIPG | |
| SCHEMBL23529729 | 0.81 | SNCA (0.38) | IDO1TDO2IRAK4CA1CA2 | |
| SCHEMBL30928610 | 0.80 | IDO1 (0.39) | IDO1TDO2IRAK4LPLLIPG | |
| SCHEMBL28807184 | 0.78 | HDAC3 (0.44) | IDO1TDO2IRAK4FLT3LPL | |
| SCHEMBL23638410 | 0.78 | FFAR1 (0.35) | IDO1TDO2IRAK4LPLLIPG | |
| SCHEMBL23633173 | 0.78 | LPL (0.36) | IDO1TDO2IRAK4LPLLIPG | |
| SCHEMBL23638499 | 0.78 | IDO1 (0.33) | IDO1TDO2IRAK4LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| CN-114901664-B | Pyridone compounds and uses thereof | 南京再明医药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2022206730-A1 | PYRIMIDOPYRAZINE COMPOUND AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-115141202-A | Pyrimidopyrazinone compounds and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-114901664-A | Pyridone compound and application thereof | 江苏先声药业有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021139775-A1 | PYRIDONE COMPOUND AND APPLICATION | 江苏先声药业有限公司 | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228491-A1 | METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | MAT1A, AMD1, MAT2B | IDO1 846/4885TDO2 1172/4885IRAK4 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.